In vivo Volumetric, DTI and 1H MRS Rat Brain Protocol for Monitoring Early Neurodegeneration and Efficacy of the Used Therapy
Author:
Tvrdík Tomáš12, Melicherčík Ľubomír12, Šebeková Katarína3, Szabó Jakub3, Maková Marianna1, Gogola Daniel4, Kašparová Svatava1
Affiliation:
1. 1 Central Laboratories, Faculty of Chemical and Food Technology , Slovak University of Technology in Bratislava , Radlinského 9, 81237 , Bratislava , Slovakia 2. 2 Department of Radiology , Faculty of Medicine of Comenius University in Bratislava, Slovak Medical University and University Hospital Bratislava , Mickiewiczova 13, 81369 Bratislava , Slovakia 3. 3 Institute of Molecular Biomedicine , Faculty of Medicine of Comenius University in Bratislava , Sasinkova 4, 81108 , Bratislava , Slovakia 4. 4 Institute of Measurement Science, Slovak Academy of Sciences , Dúbravská cesta 9, 841 04 Bratislava , Slovakia
Abstract
Abstract
The aim of our study was to develop a multimodal experimental protocol for in vivo imaging and metabolic parameters (MRI, DTI and 1H MRS) in an animal model of neurodegeneration. We have successfully developed the protocol for simultaneous DTI/MRI/1H MRS measurement to ensure unaltered conditions for repeatable non-invasive experiments. In this experiment, diffusion tensor imaging, spectroscopic and volumetric “bio-markers” were generated in the brain for the D-galactose model of “age-related dementia”. The hippocampal relative volume, taurine and myo-inositol relative concentrations were found to be significant predictors contributing to the differences between the groups of rats treated with D-galactose in simulated “neurodegeneration”, even in response to the applied Huperzine A therapy.
Publisher
Walter de Gruyter GmbH
Subject
Instrumentation,Biomedical Engineering,Control and Systems Engineering
Reference58 articles.
1. Sadigh-Eteghad, S., Majdi, A., McCann, S. K., Mahmoudi, J., Vafaee, M. S., Macleod, M. R. (2017). Correction: D-galactose-induced brain ageing model: A systematic review and meta-analysis on cognitive outcomes and oxidative stress indices. PloS One, 12 (12), e0190328. https://doi.org/10.1371/journal.pone.0190328 2. Damar, U., Gersner, R., Johnstone, J. T., Schachter, S., Rotenberg, A. (2016). Huperzine A as a neuroprotective and antiepileptic drug: A review of preclinical research. Expert Review of Neurotherapeutics, 16 (6), 671-680. https://doi.org/10.1080/14737175.2016.1175303 3. Ruan, Q., Hu, X., Ao, H., Ma, H., Gao, Z., Liu, F., Kong, D., Bao, Z., Yu, Z. (2014). The neurovascular protective effects of huperzine A on D-galactose-induced inflammatory damage in the rat hippocampus. Gerontology, 60 (5), 424-439. https://doi.org/10.1159/000358235 4. Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., Ferri, C. P. (2013). The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s & Dementia, 9 (1), 63-75.e2. https://doi.org/10.1016/j.jalz.2012.11.007 5. Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P. (2010). EFNS guidelines for the diagnosis and management of Alzheimer’s disease. European Journal of Neurology, 17 (10), 1236-1248. https://doi.org/10.1111/j.1468-1331.2010.03040.x
|
|